Exemestane

• Discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control: A ra… Recruiting
  2023-504141-31-00 Phase II 1 country Institut fuer Klinische Krebsforschung IKF GmbH
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac… Recruiting
  2022-502046-28-00 Phase III 7 countries F. Hoffmann-La Roche AG
• TRAK-ER_A randomised trial of early detection of molecular relapse with circulating tumour DNA tracking and treatment with palbociclib plus … Recruiting
  2024-517414-15-00 Phase II 1 country The Royal Marsden NHS Foundation Trust
• CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE… Recruiting
  2022-500764-35-00 Phase IV 1 country Institut Für Frauengesundheit GmbH
• ExclUsive endocRine therapy Or radiation theraPy for women aged ≥70 years with luminal A-like early stage breast cancer (EUROPA): a randomiz… Recruiting
  2023-508094-88-00 Phase III 1 country University Of Florence
• Trial that evaluates the interest of interruption versus maintaining the treatment of aromatase inhibitors in patients with metastatic low g… Recruiting
  2024-512629-97-00 Phase II 1 country Centre Leon Berard
• LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting
  2022-502706-33-00 Phase IV 1 country Grupo Espanol De Investigacion En Cancer De Mama
• A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer. Ended
  2022-503001-38-01 Phase III 2 countries Novartis Pharma AG
• A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II… Ended
  2024-516530-36-00 Phase III 1 country Cancer Trials Ireland
• Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-… Ended
  2024-513540-29-00 Phase III 5 countries Alliance Foundation Trials LLC
• A Study to Evaluate the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician’s Choice of Endocrine Therapy Plus E… Ended
  2023-506821-12-00 Phase III 4 countries Genentech Inc.
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended
  2022-501024-20-00 Phase III 14 countries Astrazeneca AB
• Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence Ended
  2024-514480-26-00 Phase II 1 country Unicancer
• A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu… Ended
  2022-500014-26-00 Phase III 8 countries F. Hoffmann-La Roche AG
• Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer wit… Ended
  2024-511209-49-00 Phase IV 1 country Universitaetsklinikum Ulm AöR
• Multi-drug treatment for breast cancer patients with brain metastases Ended
  2024-510703-11-00 Phase II 1 country Unicancer
• EMBER-3 A Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Participants with ER+, HER… Ended
  2023-506786-63-00 Phase III 8 countries Eli Lilly & Co.
• A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk… Ended
  2023-505223-31-00 Phase II 7 countries European Organisation For Research And Treatment Of Cancer
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended
  2023-509671-17-00 Phase III 16 countries Eli Lilly & Co.
• PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended
  2024-510704-37-00 Phase III 1 country Unicancer
• PREDIX Luminal B - Neoadjuvant response-guided treatment of estrogen receptor positive tumors with high proliferation or slow proliferation … Ended
  2024-519019-32-00 Phase II 1 country Karolinska University Hospital
• "A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone… Ended
  2024-515368-29-00 Phase III 1 country Fundacion Grupo Espanol De Investigacion En Cancer De Mama
• Study to evaluate the effect of metformin in the prevention of hyperglycemia in HR[+]/HER2[–] PIK3CA-mutated advanced breast cancer patients… Ended
  2024-511295-33-00 Phase II 1 country Medica Scientia Innovation Research S.L.
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan… Ended
  2023-506487-13-00 Phase III 14 countries Pfizer Inc.

Showing 25–48 of 48 trials